# Different types of exercise and myocardial angiogenesis regulation: A scoping review of cardiac‐specific evidence in animal models

**Authors:** Putri Karisa, Nova Sylviana, Aziiz Mardanarian Rosdianto, Hanna Goenawan, Mas Rizky Anggun Adipurna Syamsunarno, Setiawan

PMC · DOI: 10.14814/phy2.70775 · Physiological Reports · 2026-03-04

## TL;DR

This review explores how different types of exercise affect heart blood vessel growth in healthy animals, highlighting varied molecular responses.

## Contribution

The study maps cardiac-specific angiogenesis regulators across exercise types in healthy animal models.

## Key findings

- Aerobic exercise consistently upregulates the VEGF-VEGFR axis and related signaling pathways.
- Interval/HIIT exercise activates endothelial markers and increases vascular indices.
- Resistance/combined training involves AMPK-PGC-1α and VEGFR2 pathways but has limited mechanistic data.

## Abstract

Exercise promotes myocardial angiogenesis, yet molecular responses vary by modality, and cardiac‐specific evidence in healthy models remains fragmented. This study aimed to map biomolecular regulators of myocardial/coronary angiogenesis across exercise types in healthy animal models. PRISMA‐ScR scoping review. Literature searches were conducted in PubMed, Scopus, and SpringerLink. Eligible studies were structured exercise interventions in physiologically healthy animals reporting myocardial/coronary tissue angiogenesis biomarkers and/or structural microvascular indices; disease models and studies reporting only circulating markers were excluded. FITT parameters and outcomes were charted and synthesized by exercise type. From 4674 records, 23 studies were included across swimming, continuous treadmill/running, interval/HIIT, resistance, and combined training. Aerobic protocols most consistently upregulated the VEGF‐VEGFR axis with downstream PI3K/Akt‐eNOS/NO and context‐dependent HIF‐1α signaling. Interval/HIIT showed prominent endothelial activation (e.g., miR‐126 and CD34/KDR) alongside increased vascular indices. Resistance/combined training was less represented, but implicated AMPK‐PGC‐1α/FNDC5‐irisin signaling, VEGFR2/FLK‐1 upregulation, and eNOS/NO support in combined protocols. Exercise modality appears to recruit distinct upstream regulators that converge on myocardial angiogenic remodeling; evidence is dominated by male‐only models, and mechanistic data for resistance/combined training remain limited.

## Linked entities

- **Genes:** KDR (kinase insert domain receptor) [NCBI Gene 3791], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], NOS3 (nitric oxide synthase 3) [NCBI Gene 4846], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], MIR126 (microRNA 126) [NCBI Gene 406913], CD34 (CD34 molecule) [NCBI Gene 947], KDR (kinase insert domain receptor) [NCBI Gene 3791], PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891], FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995], KDR (kinase insert domain receptor) [NCBI Gene 3791], KDR (kinase insert domain receptor) [NCBI Gene 3791]

## Full-text entities

- **Genes:** Nfkb1 (nuclear factor kappa B subunit 1) [NCBI Gene 81736] {aka EBP-1, NF-kB, NFKB-p50, p50}, bnc2 (basonuclin zinc finger protein 2) [NCBI Gene 559327] {aka bnp, coral, crl, fi18b05, poppy, si:dkey-114f6.1}, raf1a (Raf-1 proto-oncogene, serine/threonine kinase a) [NCBI Gene 30716] {aka c-raf, craf, raf1}, Nos2 (nitric oxide synthase 2) [NCBI Gene 24599] {aka Nos2a, iNos}, kdrl (kinase insert domain receptor like) [NCBI Gene 796537] {aka flk, flk-1, flk1, kdr, kdra, vegfr-2}, Pik3cg (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma) [NCBI Gene 298947] {aka Pi3k}, ppargc1a (peroxisome proliferator-activated receptor gamma, coactivator 1 alpha) [NCBI Gene 553418] {aka PGC-1, PGC-1alpha, PGC1, gb:dq017637, ppargc1al}, kdr (kinase insert domain receptor (a type III receptor tyrosine kinase)) [NCBI Gene 554230] {aka flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Src (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 83805], KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, Igf1 (insulin-like growth factor 1) [NCBI Gene 24482] {aka IGF}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 54250] {aka Fgf-2, Fgf2a, bFGF}, hdac4 (histone deacetylase 4) [NCBI Gene 568877] {aka wu:fa96d08, wu:fc56f08, zgc:152701}, Ppargc1a (PPARG coactivator 1 alpha) [NCBI Gene 83516] {aka LRPGC1, PGC-1v, PGCvf, PGCvf-1, PGCvf1, Ppargc1}, Cdh5 (cadherin 5) [NCBI Gene 307618], Rps6kb1 (ribosomal protein S6 kinase B1) [NCBI Gene 83840] {aka p70 S6K-alpha}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Angpt1 (angiopoietin 1) [NCBI Gene 89807] {aka Agpt, Agpt1, Ang-1}, Mir29a (microRNA 29a) [NCBI Gene 100314230] {aka rno-mir-29a}, Cebpb (CCAAT/enhancer binding protein beta) [NCBI Gene 24253] {aka Il6dbp, NF-IL6, TCF5}, Nrg1 (neuregulin 1) [NCBI Gene 112400], angpt2b (angiopoietin 2b) [NCBI Gene 114408] {aka ang2, angpt2}, Spred1 (sprouty-related, EVH1 domain containing 1) [NCBI Gene 296072], Cd34 (CD34 molecule) [NCBI Gene 305081], Mef2c (myocyte enhancer factor 2C) [NCBI Gene 499497] {aka RGD1563119}, Vegfb (vascular endothelial growth factor B) [NCBI Gene 89811], CD34 (CD34 molecule) [NCBI Gene 947], Pik3r2 (phosphoinositide-3-kinase regulatory subunit 2) [NCBI Gene 29741], Tek (TEK receptor tyrosine kinase) [NCBI Gene 89804] {aka Tie-2, Tie2}, Thbs1 (thrombospondin 1) [NCBI Gene 445442] {aka TSP-1, Tsp1}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Fstl1 (follistatin-like 1) [NCBI Gene 79210] {aka Frp, Fstl}, Fndc5 (fibronectin type III domain containing 5) [NCBI Gene 260327], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, Angpt2 (angiopoietin 2) [NCBI Gene 89805] {aka Agpt2, Ang-2}, ADRB3 (adrenoceptor beta 3) [NCBI Gene 155] {aka BETA3AR}, Flt1 (Fms related receptor tyrosine kinase 1) [NCBI Gene 54251] {aka FLT-1, VEGFR-1}, Ang2 (angiogenin, ribonuclease A family, member 2) [NCBI Gene 497229] {aka Ang, Raa2}, edn1 (endothelin 1) [NCBI Gene 58032] {aka et-1, fb14d01, wu:fb14d01}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, Ang (angiogenin) [NCBI Gene 305843] {aka Ang1}, Pecam1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 29583] {aka CD31, Pecam}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, src (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 325084] {aka c-src, fc54g04, p60-Src, sb:cb864, wu:fc54g04}, Dip2a (Dip2 acetate--CoA ligase A) [NCBI Gene 690211], mir126a (microRNA 126a) [NCBI Gene 100033640] {aka dre-mir-126, dre-mir-126a, mir-126a, mir126}, Hif1a (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 29560] {aka HIF1-alpha, MOP1}, Mir126b (microRNA 126b) [NCBI Gene 100314237] {aka Mir126, Mir126a, rno-mir-126, rno-mir-126a}, hif1aa (hypoxia inducible factor 1 subunit alpha a) [NCBI Gene 797150], Mir222 (microRNA 222) [NCBI Gene 100314059] {aka rno-mir-222}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, spred1 (sprouty related EVH1 domain containing 1) [NCBI Gene 406513] {aka fb14c08, fj51c03, wu:fb14c08, wu:fj51c03, zgc:85707}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, fgf2 (fibroblast growth factor 2) [NCBI Gene 404231], Slc2a4 (solute carrier family 2 member 4) [NCBI Gene 25139] {aka Glut4}, tesca (tescalcin a) [NCBI Gene 406633] {aka fc43f02, tesc, wu:fc43f02, zgc:77495}
- **Diseases:** diabetes (MESH:D003920), ischemic (MESH:D002545), fibrosis (MESH:D005355), PK (MESH:C564858), cardiometabolic disease (MESH:D024821), injury (MESH:D014947), inflammation (MESH:D007249), CHD (MESH:D003327), CT (MESH:D000095027), Hypoxia (MESH:D000860), loss of muscle mass (MESH:C536030), obesity (MESH:D009765), Hypoxic (MESH:D002534), stroke (MESH:D020521), noncommunicable diseases (MESH:D000073296), fatigue (MESH:D005221), NS (MESH:D056770), hypertrophy (MESH:D006984), myocardial ischemia (MESH:D017202), myocardial infarction (MESH:D009203), muscle hypertrophy (MESH:C536106), left ventricular wall hypertrophy (MESH:D017379), hypertension (MESH:D006973), heart failure (MESH:D006333), coronary artery disease (MESH:D003324), LI (MESH:D016864), HI (MESH:C538424), cardiac muscle hypertrophy (MESH:D006332), cardiac remodeling (MESH:D020257)
- **Chemicals:** MDA (MESH:D015104), adrenaline (MESH:D004837), MIT (MESH:C011506), O2 (MESH:D010100), norepinephrine (MESH:D009638), cholesterol (MESH:D002784), nitric oxide (MESH:D009569), water (MESH:D014867), malondialdehyde (MESH:D008315), NO (MESH:D009614), H&amp;E (MESH:D006371), CT (-), calcium (MESH:D002118), glucose (MESH:D005947), Steroid (MESH:D013256), ATP (MESH:D000255), lipids (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955]
- **Mutations:** T45)T
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), TESC-C — Mus musculus (Mouse), Finite cell line (CVCL_S361)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960063/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960063/full.md

## References

130 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960063/full.md

---
Source: https://tomesphere.com/paper/PMC12960063